CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study
Authors
Pezzani M.D., Gutiérrez-Gutiérrez B., Viale P., Hsueh P.-R., Ruiz-Garbajosa P., Venditti M., Tumbarello M., Navarro-Francisco C., Calbo E., Akova M., Giamarellou H., Oliver A., Almirante B., Gasch O., Martínez-Martínez L., Schwaber M.J., Daikos G., Pitout J., Peña C., Hernández-Torres A., Doi Y., Pérez F., Tuon F.F., Tacconelli E., Carmeli Y., Bonomo R.A., Pascual Á., Paterson D.L., Rodríguez-Baño J., del Toro M.D., Gálvez J., Falcone M., Russo A., Karaiskos I., Trecarichi E.M., Losito A.R., García-Vázquez E., Gómez J., Roilides E., Iosifidis E., Pournaras S., Prim N., Navarro F., Mirelis B., Origüen J., Juan R.S., Fernández-Ruiz M., Almela M., de la Calle C., Martínez J.A., Morata L., Larrosa N., Puig-Asensio M., Bou G., Molina J., González V., Bermejo J., Rucci V., de Gopegui E.R., Marinescu C.I., Fariñas M.C., Cano M.E., Gozalo M., Paño-Pardo J.R., Mora-Rillo M., Gómez-Zorrilla S., Tubau F., Tsakris A., Zarkotou O., Antoniadou A., Poulakou G., Souli M., Lowman W., Virmani D., Torre-Cisneros J., Machuca I., Gracia-Ahufinger I., Azap Ö.K., Helvaci Ö., Sahin A.O., Cantón R., Pintado V., Bartoletti M., Giannella M., Peter S., Hamprecht A., Badia C., Xercavins M., Fontanals D., Jové E., ESGBIS/REIPI/INCREMENT Group Harris P.N.A.
Publication date
1 January 2017
Publisher
'Elsevier BV'
Doi
Cite
Abstract
We describe regional differences in therapy for bloodstream infection (BSI) caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE). Patients (n = 1482) in 12 countries from an observational study of BSI caused by ESBL-E or CPE were included. Multivariate logistic regression was used to calculate adjusted odds ratios (aORs) for the influence of country of recruitment on empirical use of β-lactam/β-lactamase inhibitors (BLBLIs) or carbapenems, targeted use of BLBLIs for ESBL-E and use of targeted combination therapy for CPE. Compared with Spain, BLBLI use for empirical therapy was least likely in sites from Israel (aOR 0.34, 95% CI 0.14–0.81), Greece (aOR 0.49, 95% CI 0.26–0.94) and Canada (aOR 0.31, 95% CI 0.11–0.88) but more likely in Italy (aOR 1.58, 95% CI 1.11–2.25) and Turkey (aOR 2.09, 95% CI 1.14–3.81). Empirical carbapenem use was more likely in sites from Taiwan (aOR 1.73, 95% CI 1.03–2.92) and USA (aOR 1.89, 95% CI 1.05–3.39) and less likely in Italy (aOR 0.44, 95% CI 0.28–0.69) and Canada (aOR 0.10, 95% CI 0.01–0.74). Targeted BLBLIs for ESBL-E was more likely in Italian sites. Treatment at sites within Israel, Taiwan, Turkey and Brazil was associated with less combination therapy for CPE. Although this study does not provide precise data on the relative prevalence of ESBL-E or CPE, significant variation in therapy exists across countries even after adjustment for patient factors. Better understanding of what influences therapeutic choices for these infections will aid antimicrobial stewardship efforts. © 2017 Elsevier B.V. and International Society of Chemotherap
Similar works
Full text
Available Versions
University of Thessaly Institutional Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ir.lib.uth.gr:11615/73907
Last time updated on 13/02/2023
Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lib.uoa.gr:uoadl:3108200
Last time updated on 10/02/2023